Shingrix (Herpes Zoster vaccine Recombinant, adjuvanted)

Product menu

Every week, patients become eligible for the Shingles National Immunisation Programme

Why wait? Take action to help protect your patients from shingles as soon as they become eligible

Vaccine uptake in eligible cohorts in England (data from UK Health Security Agency)

Severely Immuncompromised patients aged ≥ 50 years

19.3%

of eligible severely immunocompromised patients who turned 50 and over from 1st Sep 2023 to 31st Aug 2024 had received their first dose by 23rd Oct 20241

Immunocompetent 65-year-olds

29.9%

of adults who turned 65 between 1st Sep 2023 and 31st Aug 2024 had received their first dose by 23rd Oct 20241

Immunocompetent 70-year-olds

41.2%

of adults who turned 70 between 1st Sep 2023 and 31st Aug 2023 had received their first dose by 23rd Oct 20241

From 1st September 2025, eligibility for shingles vaccination expands to include all severely immunocompromised individuals aged 18 and over2,3

NA
  • Implementation of the Programme is expected to reduce the burden of shingles for your patients and practice
    • In September 2013, the Shingles National Immunisation Programme was introduced into the routine schedule for adults aged 70 years with a phased catch-up programme for 71-79 years.4
    • In the first 5 years (when a live shingles vaccine was used), there were 40,500 fewer GP consultations and 1,840 fewer hospitalisations for shingles and post-herpetic neuralgia in England.4
  • The programme also provides the opportunity to:
    • Earn Quality and Outcomes Framework (QOF) points5
    • Receive an item of service fee per dose of shingles vaccination administered in line with national guidance6

Visit illuminate for free, peer-led and practical resources

Visit illuminate to access helpful resources and tools designed to support the implementation of the Shingles National Immunisation Programme in your practice. This is a GSK-owned and funded website, containing promotional information.

NA

References:

  1. UK Health Security Agency. Shingrix vaccine uptake report (adults eligible from September 2023 to August 2024 and vaccinated to the end of October 2024): England. Updated 31 July 2025.
  2. UKHSA Green Book: Shingles (herpes zoster): the green book chapter
  3. UK Health Security Agency. Shingles vaccination programme: expansion of Shingrix vaccine eligibility to all those who are severely immunosuppressed and aged 18 years and over. Published July 2025.
  4. Andrews N, Stowe J, Kuyumdzhieva G, et al. BMJ Open 2020; 10e037458: 1-15.
  5. NHS England. Quality and Outcomes Framework guidance for 2025/2026. Last updated March 2025. Available at https://www.england.nhs.uk/publication/quality-and-outcomes-framework-guidance-for-2025-26/ (Last accessed: July 2025)
  6. UK Health Security Agency: Introduction of Shingrix vaccine for the whole programme and expansion of eligible cohorts letter. Published July 2023.

Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/ or search for MHRA Yellowcard in the Google Play or Apple App store. Adverse events should also be reported to GSK on 0800 221 441 or UKSafety@gsk.com

SHINGRIX is owned by or licensed to the GSK group of companies.
© 2025 GSK group of companies or its licensor.
Trade marks are owned by or licensed to the GSK group of companies.

September 2025 | PM-GB-SGX-WCNT-230025 (V5.0)